StockTipsArenaBeta

BUY Jubilant Pharmova Limited — Ventura

BUYJubilant Pharmova Limited
Jubilant Pharmova share price target & all analyst calls

byVenturaHorizon: NA (inferred 1 year)15 Jan 2026via Institutional / Brokerage Research

Entry₹1,066.3Inferred
Target₹1,557
Total upside +46.02%
Stop lossNot given
CMP₹938.32d ago
Active-12.00%+65.94%upside left 3 mo left
Follow Ventura for new calls(49% target hit, 130 closed calls)Get alertsWatch JUBLPHARMA for new buy/sell callsGet alertsSee 2 other Long-term calls on JUBLPHARMASee 274 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 10:51 pm IST
7 supporting11 neutral7 opposing
Supports the BUY call (7)

Jubilant Pharmova radiopharma unit to invest CAD 94.5 million to double RUBY-FILL production

NewsCnbc-Tv18·8 Oct · 2w ago

(opens in new tab)

1 other SEBI-registered advisor has an active long-term BUY call on this stock

Advisor consensus · same horizon·8 Feb · 9mo ago

Neutral / worth noting (11)

Jubilant Pharmova eyes $150 million through rupee debt sale, bankers say

NewsHbl·23 Oct · 2d ago

(opens in new tab)

Jubilant Pharmova approves ₹800 crore NCD issue through private placement

NewsHbl·13 Oct · 2w ago

(opens in new tab)

Jubilant Pharmova block deal: Quant Mutual Fund offloads Rs 190 crore stake amid Rs 800 crore fundraising plan; Abakkus buys 11 lakh shares

NewsEt-Markets·12 Oct · 2w ago

(opens in new tab)

Jubilant Pharmova plans to issue secured or unsecured non-convertible debentures via private placement.

BSE · Board Meeting·12 Oct · 2w ago

(opens in new tab)
Weighs against the BUY call (7)

Long-term trend bearish — 200-day average falling over the past quarter

Technicals · trend·23 Oct · 2d ago

Quant MF sells Jubilant Pharmova stake for over ₹100 crore; stock falls over 2%

NewsHbl·13 Oct · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Jubilant Pharmova

All analyst calls on Jubilant Pharmova

More from Ventura

Every call and its outcome